Nonspecific anti-inflammatories like steroids might be entirely sidelined for mild-to-moderate chronic hand eczema now that three targeted topical agents are available.
Merz Therapeutics, a business of Merz Group and a leader in the field of neurotoxins, today announced that Health Canada approved XEOMIN® (incobotulinumtoxinA) for the treatment of post-stroke lower ...